Wicki A - Search Results

1

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C. Wicki A, et al. Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7. Clin Cancer Res. 2012. PMID: 22065082

2

Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton.

Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Wicki A, et al. Cancer Cell. 2006 Apr;9(4):261-72. doi: 10.1016/j.ccr.2006.03.010. Cancer Cell. 2006. PMID: 16616332 Free article.

3

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Mäcke HR. Wild D, et al. Among authors: wicki a. J Nucl Med. 2006 Dec;47(12):2025-33. J Nucl Med. 2006. PMID: 17138746 Free article.

4

The potential role of podoplanin in tumour invasion.

Wicki A, Christofori G. Wicki A, et al. Br J Cancer. 2007 Jan 15;96(1):1-5. doi: 10.1038/sj.bjc.6603518. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179989 Free PMC article. Review.

5

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Mäcke HR, Christofori G. Wicki A, et al. Clin Cancer Res. 2007 Jun 15;13(12):3696-705. doi: 10.1158/1078-0432.CCR-06-2965. Clin Cancer Res. 2007. PMID: 17575235

6

NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.

Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, Kren A, Went P, Derksen PW, Berns A, Jonkers J, Christofori G. Lehembre F, et al. Among authors: wicki a. EMBO J. 2008 Oct 8;27(19):2603-15. doi: 10.1038/emboj.2008.178. Epub 2008 Sep 4. EMBO J. 2008. PMID: 18772882 Free PMC article.

7

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR. Wild D, et al. Among authors: wicki a. J Nucl Med. 2010 Jul;51(7):1059-67. doi: 10.2967/jnumed.110.074914. J Nucl Med. 2010. PMID: 20595511 Free article.

8

Kras in metastatic colorectal cancer.

Wicki A, Herrmann R, Christofori G. Wicki A, et al. Swiss Med Wkly. 2010 Nov 19;140:w13112. doi: 10.4414/smw.2010.13112. eCollection 2010. Swiss Med Wkly. 2010. PMID: 21104470 Free article. Review.

9

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C. Mamot C, et al. Among authors: wicki a. J Drug Target. 2012 Jun;20(5):422-32. doi: 10.3109/1061186X.2012.680960. Epub 2012 Apr 23. J Drug Target. 2012. PMID: 22519893

10

Targeted therapies in breast cancer.

Wicki A, Rochlitz C. Wicki A, et al. Swiss Med Wkly. 2012 Apr 27;142:w13550. doi: 10.4414/smw.2012.13550. eCollection 2012. Swiss Med Wkly. 2012. PMID: 22544433 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page